ArticleHeliyon2024
Preparation, process optimisation, stability and bacteriostatic assessment of composite nanoemulsion containing corosolic acid.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Stearylamine-Coated Cationic Phyto-Microemulsions Enhance Resveratrol Ocular Delivery for Glaucoma Therapy: Experimental and Preclinical Insights.AAPS PharmSciTech · 2026Article
- Optimized solid lipid nanoparticles for co-delivery of gentamicin and doxycycline: a novel approach to combat intracellular brucella abortus infections.World journal of microbiology & biotechnology · 2025Article
- Chemical composition, characterization, and antimicrobial properties ofFrontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corosolic acid (CA), a pentacyclic triterpenoid, exhibits remarkably low hydrophilicity, restricting its application in aqueous systems. To enhance its hydrophilicity, we optimised nanoemulsion preparation conditions, resulting in a stable corosolic acid nanoemulsion system. By screening the oil phase, surfactant, and cosurfactant, along with investigating the mass ratio of surfactant and cosurfactant and the preparation temperature, we achieved an optimal corosolic acid nanoemulsion. We measured the particle size, polydispersity coefficient, and Zeta potential of the optimised formulation. The nanoemulsion's sustained-release effect, stability, and antibacterial activity were subsequently examined. The optimised formulation comprised ethyl oleate, cremophor EL, and Tween 80 (1.5:1), combined with ethanol in a ratio of 1:9:2.25 (w/w/w), and was prepared at 30 °C. This optimised corosolic acid nanoemulsion exhibited uniform particle size distribution, favourable dispersion, and notable slow-release capabilities. Importantly, the nanoemulsion demonstrated exceptional stability. In comparison to the positive control's bacteriostatic zone diameter, it was evident that the CA nanoemulsion (1.06 ± 0.11 mm) and blank nanoemulsion (1.03 ± 0.05 mm) both displayed notable inhibitory activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.